Core Insights - The "Annual Outstanding Biopharmaceutical Company" award recognizes companies with independent core technologies, continuous innovation, and effective translation of research results into clinical or commercial applications [3] Company Overview - Heptares Therapeutics is a biopharmaceutical company focused on the research, commercialization, and global operation of innovative drugs, particularly in the fields of oncology and immune diseases [3] - The company has developed a strong pipeline of innovative and differentiated antibody drugs using its robust core technology platform [3] Technology and Innovation - Heptares Therapeutics utilizes its proprietary Harbour Mice® platform to generate fully human antibodies with two heavy chains and two light chains (H2L2) as well as fully human heavy chain antibodies (HCAb) [3] - The company has also developed an immune cell connector platform (HBICE®) based on HCAb to create next-generation bispecific antibodies, achieving antitumor efficacy that traditional combination therapies cannot reach [3] - The combination of these antibody development platforms and single-cell cloning platforms forms a unique and efficient research engine for next-generation innovative therapeutic antibodies [3]
和铂医药荣获“格隆汇金格奖·年度卓越生物医药企业”奖